Subtopic Deep Dive
IL28B Genetic Variation in HCV Clearance
Research Guide
What is IL28B Genetic Variation in HCV Clearance?
IL28B genetic variation refers to single nucleotide polymorphisms in the IFNL3/IL28B gene that predict spontaneous clearance of hepatitis C virus and response to interferon-based therapy.
Genome-wide association studies identified IL28B SNPs as key predictors of HCV treatment success with pegylated interferon-α and ribavirin. These variants influence type III interferon production and viral clearance rates. Over 10 major papers since 2009, including Ge et al. (3506 citations) and Thomas et al. (2140 citations), established this link.
Why It Matters
IL28B genotyping personalizes HCV therapy by identifying patients likely to respond to interferon-based regimens, optimizing treatment allocation before direct-acting antiviral era (Ge et al., 2009; Tanaka et al., 2009). It guides clinical decisions in resource-limited settings where genotyping costs less than ineffective therapy (Suppiah et al., 2009). Post-DAA, it informs studies on spontaneous clearance predictors for vaccine development (Thomas et al., 2009).
Key Research Challenges
Ethnic Variability in SNP Effects
IL28B SNP associations differ across populations, complicating universal predictors (Tanaka et al., 2009). Studies show stronger effects in Europeans than Asians, requiring ancestry-specific models. This variability hinders global treatment guidelines.
Transition to DAA Therapies
IL28B relevance diminished with direct-acting antivirals like telaprevir and ledipasvir-sofosbuvir, shifting focus from interferon response (Jacobson et al., 2011; Afdhal et al., 2014). Research must re-evaluate its role in combination regimens. Persistent challenges include retreatment predictions.
Mechanistic Pathways Unclear
Exact mechanisms linking IL28B variants to interferon signaling and viral clearance remain partially understood despite GWAS (Ge et al., 2009; Thomas et al., 2009). Functional studies are limited by in vivo models. Integrating with type I interferon pathways adds complexity (McNab et al., 2015).
Essential Papers
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge, Jacques Fellay, Alexander Thompson et al. · 2009 · Nature · 3.5K citations
Type I interferons in infectious disease
Finlay W. McNab, Katrin D. Mayer-Barber, Alan Sher et al. · 2015 · Nature reviews. Immunology · 2.6K citations
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Shiv Kumar Sarin, Manoj Kumar, George Lau et al. · 2015 · Hepatology International · 2.5K citations
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson, John G. McHutchison, Geoffrey Dusheiko et al. · 2011 · New England Journal of Medicine · 2.4K citations
BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has ...
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas, Chloe L. Thio, Maureen P. Martin et al. · 2009 · Nature · 2.1K citations
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka, Nao Nishida, Masaya Sugiyama et al. · 2009 · Nature Genetics · 2.1K citations
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah, Max Moldovan, Golo Ahlenstiel et al. · 2009 · Nature Genetics · 1.8K citations
Reading Guide
Foundational Papers
Start with Ge et al. (2009, 3506 citations) for treatment prediction and Thomas et al. (2009, 2140 citations) for spontaneous clearance; these GWAS established IL28B centrality. Follow with Tanaka et al. (2009) and Suppiah et al. (2009) for replication across ancestries.
Recent Advances
Study Afdhal et al. (2014) on ledipasvir-sofosbuvir diminishing IL28B role; Messina et al. (2014) on global HCV genotypes contextualizing IL28B effects.
Core Methods
Core techniques include GWAS for SNP discovery, logistic regression for odds ratios of clearance, and genotyping via TaqMan assays (Ge et al., 2009; Tanaka et al., 2009).
How PapersFlow Helps You Research IL28B Genetic Variation in HCV Clearance
Discover & Search
Research Agent uses searchPapers and citationGraph to map IL28B-HCV literature from Ge et al. (2009, 3506 citations) as seed, revealing clusters around Thomas et al. (2009) and Tanaka et al. (2009). exaSearch uncovers ethnicity-specific studies; findSimilarPapers expands to Suppiah et al. (2009).
Analyze & Verify
Analysis Agent applies readPaperContent to extract SNP rs12979860 data from Ge et al. (2009), then verifyResponse with CoVe for claim accuracy. runPythonAnalysis performs meta-analysis on clearance rates using pandas for odds ratios; GRADE grading scores evidence strength (high for Ge et al., moderate for ethnic subsets).
Synthesize & Write
Synthesis Agent detects gaps in DAA-era IL28B relevance via contradiction flagging between interferon papers (Ge et al., 2009) and telaprevir trials (Jacobson et al., 2011). Writing Agent uses latexEditText and latexSyncCitations to draft review sections, latexCompile for PDF output, exportMermaid for GWAS association diagrams.
Use Cases
"Run meta-analysis on IL28B SNP odds ratios for HCV clearance across 2009 GWAS papers."
Research Agent → searchPapers('IL28B HCV clearance') → Analysis Agent → readPaperContent(Ge et al., Thomas et al.) → runPythonAnalysis(pandas meta-analysis with forest plot) → matplotlib odds ratio visualization.
"Write LaTeX review on IL28B predictors in interferon therapy."
Synthesis Agent → gap detection(Ge et al. vs. DAA papers) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(5 foundational papers) → latexCompile → PDF with cited bibliography.
"Find code for IL28B genotype-HCV simulation models."
Research Agent → paperExtractUrls(Suppiah et al., 2009) → paperFindGithubRepo → Code Discovery → githubRepoInspect → runPythonAnalysis(reproduce logistic regression on SNP data).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ IL28B papers) → citationGraph → GRADE all claims → structured report on clearance predictors. DeepScan applies 7-step analysis with CoVe checkpoints to verify Ge et al. (2009) vs. Tanaka et al. (2009) ethnic differences. Theorizer generates hypotheses on IL28B-type I interferon interactions from McNab et al. (2015).
Frequently Asked Questions
What is the definition of IL28B genetic variation in HCV?
IL28B genetic variation denotes SNPs like rs12979860 in IFNL3/IL28B that predict HCV spontaneous clearance and interferon therapy response (Ge et al., 2009; Thomas et al., 2009).
What methods identified IL28B associations?
Genome-wide association studies (GWAS) scanned for variants linked to peginterferon-ribavirin response and spontaneous clearance (Tanaka et al., 2009; Suppiah et al., 2009).
What are key papers on IL28B-HCV?
Ge et al. (2009, Nature, 3506 citations) on treatment clearance; Thomas et al. (2009, Nature, 2140 citations) on spontaneous clearance; Tanaka et al. (2009, Nature Genetics, 2133 citations) on Japanese cohorts.
What open problems remain?
IL28B mechanistic details post-DAA era, ethnic interactions, and integration with HCV genotypes need further study (Afdhal et al., 2014; Messina et al., 2014).
Research Hepatitis C virus research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching IL28B Genetic Variation in HCV Clearance with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hepatitis C virus research Research Guide